Sugi Predict

Sugi Predict / Compounds / SCHEMBL177352

SCHEMBL177352

SCHEMBL177352

CC(=O)Oc1ccc(-c2ccc(Br)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.63
▸ LMNA P02545 5/20 0.57
▸ GAA P10253 2/20 0.53
▸ MAPT P10636 5/20 0.52
▸ POLB P06746 2/20 0.52
▸ PKM P14618 1/20 0.52
▸ MEN1 O00255 3/20 0.50
▸ KMT2A Q03164 3/20 0.50
▸ RAB9A P51151 2/20 0.50
▸ ELANE P08246 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ RXFP1 Q9HBX9 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.49
▸ CFD P00746 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ HSP90AA1 P07900 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.46
▸ TTR P02766 1/20 0.46
▸ TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL154474 0.94 LMNA (0.64) HSD17B10LMNAGAAMAPTPOLB
SCHEMBL11579928 0.91 LMNA (0.61) HSD17B10LMNAGAAMAPTPOLB
SCHEMBL28599109 0.91 LMNA (0.61) HSD17B10LMNAGAAMAPTPOLB
SCHEMBL9158246 0.89 HSD17B10 (0.76) HSD17B10LMNAGAAMAPTPOLB
SCHEMBL329365 0.89 HSD17B10 (0.76) HSD17B10LMNAGAAMAPTPOLB
SCHEMBL10237396 0.88 LMNA (0.57) HSD17B10LMNAGAAMAPTPOLB
Water SCHEMBL9344643 0.87 HSD17B10 (0.73) HSD17B10LMNAGAAMAPTPOLB
SCHEMBL9780981 0.86 CFD (0.55) HSD17B10LMNAGAAMAPTPOLB
SCHEMBL21629498 0.86 ELANE (0.69) HSD17B10LMNAMAPTPOLBPKM
SCHEMBL3986385 0.85 HSD17B10 (0.50) HSD17B10LMNAGAAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-5286898-A — — None — — JP disclosed
US-20150344503-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME INFINITY PHARMACEUTICALS INC (US) 2015-12-03 — — US disclosed
EP-2492266-B1 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2015-08-26 — — EP disclosed
US-9108989-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-08-18 — — US disclosed
US-20140121183-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2014-05-01 — — US disclosed
US-8629125-B2 Inhibitors of fatty acid amide hydrolase Infinty Pharmaceuticals, Inc. (US) 2014-01-14 — — US disclosed
US-20130059819-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2013-03-07 — — US disclosed
US-8349814-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2013-01-08 — — US disclosed
US-8329675-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2012-12-11 — — US disclosed
CN-102712619-A 5-hydroxypyrimidine-4-carboxamide derivative DAIICHI SANKYO CO LTD 2012-10-03 — — CN disclosed
EP-0647592-B1 Process for the recovery of CuCN MERCK PATENT GMBH (DE) 1997-05-07 — — EP disclosed
EP-0725059-A1 2,3-DIAMINOPROPIONIC ACID DERIVATIVE SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-08-07 — — EP disclosed
EP-0647592-A1 Process for the recovery of CuCN MERCK PATENT GmbH (DE) 1995-04-12 — — EP disclosed
EP-0391212-B1 Process for preparing bifunctional Z-stilbene compounds, new bifunctional Z-stilbene compounds and their use for preparing polymers BAYER AG (DE) 1994-05-25 — — EP disclosed
EP-0390945-B1 Process for preparing 4,4'''-dihydroxyquater-phenyl or derivatives thereof SANKO KAIHATSU KAGAKU KENK (JP) 1993-11-18 — — EP disclosed
JP-H05286898-A PRODUCTION OF 4-ACRYLOXY-4'-BROMOBIPHENYL SANKO CHEM CO LTD 1993-11-02 — — JP disclosed
US-5136013-A Polyesters BAYER AKTIENGESELLSCHAFT (DE) 1992-08-04 — — US disclosed
US-5068300-A BIFUNCTIONAL STILBENE COMPOUNDS CONTAINING AT LEAST ONE Z-CONFIGURATED STILBENE GROUP, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THE PREPARATION OF POLYMERS BAYER AKTIENGESELLSCHAFT (DE) 1991-11-26 — — US disclosed
EP-0391212-A2 Process for preparing bifunctional Z-stilbene compounds, new bifunctional Z-stilbene compounds and their use for preparing polymers BAYER AG (DE) 1990-10-10 — — EP disclosed
EP-0390945-A1 Process for preparing 4,4'''-dihydroxyquater-phenyl or derivatives thereof Sanko Kaihatsu Kagaku Kenkyusho (JP) 1990-10-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344503-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME FAAH, FAAH2, ASAH1 HSD17B10 194/4885LMNA 2563/4885GAA 281/4885
US-20140121183-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 HSD17B10 163/4885LMNA 3682/4885GAA 368/4885
US-20130059819-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 HSD17B10 163/4885LMNA 3682/4885GAA 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.